Luis Pina

Luis Pina

Auto-generated profile, based on publicly available information

Luis Pina

Departamento de Radiología, Clínica Universidad de Navarra, Pamplona, España

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2011 in Insights into Imaging
Verified
Journal Article
Open access
PDF file
LALuis Apesteguía
Luis Apesteguía
LPLuis Javier Pina
Luis Javier Pina
Objective: To review the role of ultrasound-guided core-needle biopsy (CNB) in the management of breast lesions. Methods: Review of the most relevant literature on this topic. Results: This technique shows a high sensitivity value of about 97.5% and it offers many advantages over other imaging techniques to guide a biopsy: non-ionising radiation, low cost, full control of the needle in real time, accessibility in difficult locations, multidirectional punctures and excellent comfort for patients and radiologists. All of these advantages have made this technique the most widespread used to perform a biopsy for a suspicious breast lesion. The most important limitation is the failure to perform a biopsy for lesions that are not seen on ultrasound. An adequate radiological–pathological correlation is necessary to minimise the false-negative results. Conclusion: Ultrasound-guided CNB has proven to be a reliable technique for performing a biopsy for breast lesions that can be clearly seen on ultrasound.

5 April 2007 in Australasian Radiology
Verified
Journal Article
Closed access
PDF file
JNJj Noguera
Jj Noguera
PMP Martínez‐Miravete
P Martínez‐Miravete
FIF Idoate
F Idoate
LDL Díaz
L Díaz
LPL Pina
L Pina
FMF Martínez‐Regueira
F Martínez‐Regueira

1 April 2019 in Magnetic Resonance Imaging
Verified
Journal Article
Closed access
IGIgnacio González-Huebra
Ignacio González-Huebra
AEArlette Elizalde
Arlette Elizalde
AGAlejandra García-Baizán
Alejandra García-Baizán
MCMarta Calvo-Imirizaldu
Marta Calvo-Imirizaldu
AEAna Ezponda
Ana Ezponda
LPLuis Pina
Luis Pina

2 February 2002 in European Radiology
Verified
Journal Article
Closed access
PDF file
PIPina L. Insausti
Pina L. Insausti
JAJ. Alberro
J. Alberro
FRF. Regueira
F. Regueira
JIJ. Imaña
J. Imaña
IVI. Vivas
I. Vivas
RRR. Rezola
R. Rezola

14 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JLjose-manuel lopez-vega
jose-manuel lopez-vega
ILIsabel Alvarez Lopez
Isabel Alvarez Lopez
AAAntonio Antón
Antonio Antón
JIJosé Juan Illarramendi
José Juan Illarramendi
ALANTONIO LLOMBART-CUSSAC
ANTONIO LLOMBART-CUSSAC
Jesus Garcia-FoncillasJesus Garcia-Foncillas
Jesus Garcia-Foncillas
This prospective, phase II study evaluated novel biomarkers as predictors of response to bevacizumab in patients with breast cancer (BC), using serial imaging methods and gene expression analysis. Patients with primary stage II/III BC received bevacizumab 15 mg/kg (cycle 1; C1), then four cycles of neoadjuvant docetaxel doxorubicin, and bevacizumab every 3 weeks (C2–C5). Tumour proliferation and hypoxic status were evaluated using 18F-fluoro-3′-deoxy-3′-L-fluorothymidine (FLT)- and 18F-fluoromisonidazole (FMISO)-positron emission tomography (PET) at baseline, and during C1 and C5. Pre- and post-bevacizumab vascular changes were evaluated using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Molecular biomarkers were assessed using microarray analysis. A total of 70 patients were assessed for treatment efficacy. Significant decreases from baseline in tumour proliferation (FLT-PET), vascularity, and perfusion (DCE-MRI) were observed during C1 (p ≤ 0.001), independent of tumour subtype. Bevacizumab treatment did not affect hypoxic tumour status (FMISO-PET). Significant changes in the expression of 28 genes were observed after C1. Changes in vascular endothelial growth factor receptor (VEGFR)-2p levels were observed in 65 patients, with a > 20% decrease in VEGFR-2p observed in 13/65. Serial imaging techniques and molecular gene profiling identified several potentially predictive biomarkers that may predict response to neoadjuvant bevacizumab therapy in BC patients.

1 November 2014 in Radiologia
Verified
Journal Article
Closed access
LCLuis Apesteguía Ciriza
Luis Apesteguía Ciriza
LILuis Javier Pina Insausti
Luis Javier Pina Insausti